DANVERS, Mass., April 17, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported preliminary fourth quarter fiscal 2013 revenue of $43.7 million, up 17% compared to revenue of $37.3 million in the same period of fiscal 2012, and up 14% compared to revenue of $38.3 million in third quarter fiscal 2013. Abiomed also reported preliminary full fiscal year 2013 revenue of $158.1 million, up 25% compared to $126.4 million for fiscal year 2012.
Preliminary fiscal fourth quarter worldwide Impella revenue totaled $39.3 million, up 22% compared to revenue of $32.3 million during the same period of the prior year. For the full fiscal year 2013, preliminary worldwide Impella revenue totaled $140.3 million, up 31% compared to $106.9 million for fiscal year 2012.
Preliminary fiscal fourth quarter U.S. Impella revenue grew 22% to $36.5 million from $29.9 million in the prior year. During the quarter, an additional 30 hospitals purchased Impella 2.5 bringing the total to 748 U.S. Impella customer sites and an additional 55 hospitals purchased Impella CP, bringing the total Impella CP sites to 101. For the full fiscal year 2013, preliminary U.S. Impella revenue totaled $131.3 million, up 32% compared to fiscal year 2012."With an outstanding performance in the fourth quarter, we were able to exceed our annual revenue guidance for the third straight year. This reflects the strength of physician demand for Impella and the commitment of our field team to patients," said Michael R. Minogue, Chairman, President and Chief Executive Officer, Abiomed. The Company will host a conference call to discuss the fourth quarter fiscal year 2013 results on Thursday, May 2, 2013, at 8:00 a.m. ET with Michael R. Minogue, Chairman, President and Chief Executive Officer; Robert L. Bowen, Vice President and Chief Financial Officer; and Susan V. Lisa, Senior Director of Investor Relations and Corporate Development.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts